Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02789241 · ClinicalTrials.gov registry record · Phase 1

Dose-Related Inflammatory Effects of Intravenous Endotoxin in Humans

A Phase 1 study of Healthy, sponsored by Robert J Noveck, M.D..

Completed
Registry status
Phase 1
Development phase
23
Enrollment target
1
Study location

NCT02789241: Completed Phase 1 study of Healthy, sponsored by Robert J Noveck, M.D..

NCT02789241 is a Phase 1 study of Healthy that has completed, run by Robert J Noveck, M.D.. The registered enrollment target is 23 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02789241, a Phase 1 study of Healthy, has completed, sponsored by Robert J Noveck, M.D..

COMPLETED
Registry status
Phase 1
Development phase
23 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate 4-dose levels of CCRE Lot 94332B1 (0.6, 1.0, 2.0, and 4.0 ng/kg). This study is known as, an "endotoxin challenge." Thousands of healthy subjects worldwide over the last 20 years have participated in endotoxin challenge studies as part of clinical research and clinical drug development programs. This study will only test the safety and tolerability of CCRE Lot 94332B1.

Primary Outcome

Safety will be assessed by measuring heart rate.

Conditions Studied

Healthy

Interventions

  • OTHER Placebo
  • BIOLOGICAL Endotoxin

Study Locations (1)

North Carolina

  • Duke Early Phase Clinical Research (DEPRU) - Durham

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2016-08
Est. Completion 2016-10
Phase Phase 1
Robert J Noveck, M.D.

2 total trials

What the finished NCT02789241 record still lists

NCT02789241 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02789241 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT02789241 about?

NCT02789241 is a clinical study titled "Dose-Related Inflammatory Effects of Intravenous Endotoxin in Humans". The purpose of this study is to evaluate 4-dose levels of CCRE Lot 94332B1 (0.6, 1.0, 2.0, and 4.0 ng/kg). This study is known as, an "endotoxin challenge." Thousands of healthy subjects worldwide over the last 20 years have participated in endotoxin challenge studies as part of clinical research an...

What is the current status of trial NCT02789241?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2016-08. Estimated completion is 2016-10.

What conditions does trial NCT02789241 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT02789241?

The interventions under investigation include: Placebo (OTHER), Endotoxin (BIOLOGICAL).

Who is sponsoring clinical trial NCT02789241?

This trial is sponsored by Robert J Noveck, M.D., which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02789241 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02789241's enrollment target sits among peer trials

23 838th of 1090 higher than 248 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03616041 · 23 participants

    Capsule Endoscopy for Severe Hematochezia

  • NCT04348747 · 23 participants · Phase 2

    Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

  • NCT04587687 · 23 participants · Phase 2

    Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

  • NCT04715022 · 23 participants · Phase 1

    Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT02789241, the US trial registry maintained by the National Library of Medicine. NCT02789241 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.